Creative Medical Technology Holdings, INC. (CELZ) — SEC Filings

Overview

Creative Medical Technology Holdings, INC. (CELZ) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 31, 2025: Creative Medical Technology Holdings, Inc. filed an 8-K on December 26, 2025, reporting on matters submitted to a vote of security holders and financial statements/exhibits. The company, formerly known as JOLLEY MARKETING INC, is incorporated in Nevada and headquartered in Phoenix, Arizona.

Sentiment Summary

Across 28 filings, the sentiment breakdown is: 4 bearish, 23 neutral, 1 mixed. The dominant filing sentiment for Creative Medical Technology Holdings, INC. is neutral.

Filing Type Overview

Creative Medical Technology Holdings, INC. (CELZ) has filed 11 8-K, 5 DEF 14A, 6 10-Q, 4 10-K/A, 2 10-K with the SEC between Mar 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (28)

• Creative Medical Tech Files 8-K on Shareholder Votes & Exhibits — 8-K · Dec 31, 2025 Risk: low
  Creative Medical Technology Holdings, Inc. filed an 8-K on December 26, 2025, reporting on matters submitted to a vote of security holders and financial stateme
• Creative Medical Tech Files 8-K on Shareholder Votes & Financials — 8-K · Dec 19, 2025 Risk: low
  Creative Medical Technology Holdings, Inc. filed an 8-K on December 19, 2025, reporting on matters submitted to a vote of security holders and financial stateme
• CELZ Seeks Shareholder Nod for 2.79M Warrant Exercise Amid Dilution Fears — DEF 14A · Nov 13, 2025 Risk: medium
  Creative Medical Technology Holdings, Inc. (CELZ) is holding a Special Meeting on December 26, 2025, to seek stockholder approval for the exercise in full of 2,
• Creative Medical Tech: Board & Executive Compensation Changes — 8-K · Nov 12, 2025 Risk: medium
  Creative Medical Technology Holdings, Inc. announced on November 6, 2025, a change in its board of directors and executive compensation arrangements. The filing
• CELZ Losses Widen Amid Minimal Revenue, Cash Dips Despite Warrant Exercise — 10-Q · Nov 7, 2025 Risk: high
  Creative Medical Technology Holdings, Inc. (CELZ) reported a net loss of $1,235,934 for the three months ended September 30, 2025, an increase from a net loss o
• Creative Medical Tech Enters Material Agreement, Files 8-K — 8-K · Oct 31, 2025 Risk: medium
  Creative Medical Technology Holdings, Inc. entered into a material definitive agreement on October 29, 2025. The company also reported unregistered sales of equ
• CELZ Sets Dec. 18 Annual Meeting; Board Backs All Proposals — DEF 14A · Oct 30, 2025 Risk: low
  Creative Medical Technology Holdings, Inc. (CELZ) is holding its 2025 Annual Meeting of Stockholders on December 18, 2025, at 9:00 a.m. Pacific Standard Time in
• CELZ's Net Loss Widens to $4.1M Amid R&D Push, Zero Revenue — 10-Q · Aug 8, 2025 Risk: high
  CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) reported no revenue for the six months ended June 30, 2025, consistent with the prior year, indicating its pre
• Creative Medical Tech Q1 2025: Warrants and Patents — 10-Q · May 9, 2025 Risk: medium
  Creative Medical Technology Holdings, Inc. filed a 10-Q for the period ending March 31, 2025. The company reported $0.001 in revenue and had $25,000,000 in warr
• Creative Medical Tech Files 8-K — 8-K · May 6, 2025 Risk: low
  Creative Medical Technology Holdings, Inc. filed an 8-K on May 5, 2025, reporting on the submission of matters to a vote of security holders and financial state
• Creative Medical Tech Files 10-K/A Amendment — 10-K/A · Apr 25, 2025 Risk: medium
  Creative Medical Technology Holdings, Inc. filed an amendment (No. 3) to its Annual Report on Form 10-K for the fiscal year ended December 31, 2024. The filing,
• Creative Medical Technology Faces Delisting Concerns — 8-K · Apr 11, 2025 Risk: high
  Creative Medical Technology Holdings, Inc. filed an 8-K on April 11, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The f
• Creative Medical Tech Files 10-K/A Amendment — 10-K/A · Apr 4, 2025 Risk: medium
  Creative Medical Technology Holdings, Inc. filed an amendment (No. 2) to its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, on April 4,
• Creative Medical Tech Amends 2024 10-K Filing — 10-K/A · Mar 19, 2025 Risk: low
  Creative Medical Technology Holdings, Inc. filed an amendment (10-K/A) on March 19, 2025, to its annual report for the year ended December 31, 2024. This amendm
• Creative Medical Tech Holdings Files Definitive Proxy Statement — DEF 14A · Mar 17, 2025 Risk: low
  Creative Medical Technology Holdings, Inc. filed a Definitive Proxy Statement (DEF 14A) on March 17, 2025, for the fiscal year ending December 31, 2024. The com
• Creative Medical Technology Holdings, Inc. Files 2024 10-K — 10-K · Mar 14, 2025 Risk: medium
  Creative Medical Technology Holdings, Inc. filed its 2024 10-K on March 14, 2025, reporting its fiscal year ending December 31, 2024. The company, formerly Joll
• Creative Medical Tech Enters Definitive Agreement — 8-K · Mar 7, 2025 Risk: medium
  Creative Medical Technology Holdings, Inc. announced on March 6, 2025, that it entered into a material definitive agreement. The company also reported on unregi
• Creative Medical Tech Files 8-K with Corporate Updates — 8-K · Dec 26, 2024 Risk: medium
  Creative Medical Technology Holdings, Inc. filed an 8-K on December 26, 2024, reporting events that occurred on December 19, 2024. The filing indicates changes
• Creative Medical Tech Holdings Files Q3 2024 10-Q — 10-Q · Nov 8, 2024 Risk: medium
  Creative Medical Technology Holdings, Inc. filed its Q3 2024 10-Q report on November 8, 2024, covering the period ending September 30, 2024. The company, former
• Creative Medical Tech Files Definitive Proxy Statement — DEF 14A · Nov 4, 2024 Risk: low
  Creative Medical Technology Holdings, Inc. filed an amendment to its Schedule 14A on November 4, 2024, for its definitive proxy statement. The company, previous
• Creative Medical Technology Holdings Enters Material Agreement — 8-K · Oct 23, 2024 Risk: medium
  Creative Medical Technology Holdings, Inc. announced on October 22, 2024, that it entered into a material definitive agreement. The filing does not provide spec
• Creative Medical Tech Reports Minimal Revenue in Q2 2024 — 10-Q · Aug 9, 2024 Risk: high
  Creative Medical Technology Holdings, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported minimal revenue, with $0.001 million in reve
• Creative Medical Tech Files 8-K on Shareholder Votes & Financials — 8-K · Jul 25, 2024 Risk: low
  Creative Medical Technology Holdings, Inc. filed an 8-K on July 25, 2024, reporting on matters submitted to a vote of security holders and financial statements
• Creative Medical Technology Holdings Files Proxy Statement — DEF 14A · Jun 5, 2024 Risk: medium
  Creative Medical Technology Holdings, Inc. filed its definitive proxy statement on June 5, 2024, for its annual meeting on July 19, 2024. The company, formerly
• Creative Medical Technology Holdings Enters Definitive Agreement — 8-K · May 17, 2024 Risk: medium
  Creative Medical Technology Holdings, Inc. announced on May 14, 2024, that it entered into a material definitive agreement. The company also reported on unregis
• Creative Medical Technology Holdings, Inc. Files 10-Q for Q1 2024 — 10-Q · May 10, 2024 Risk: low
  CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) filed a Quarterly Report (10-Q) with the SEC on May 10, 2024. The company filed a 10-Q for the period ending M
• Creative Medical Technology Holdings, Inc. Files 10-K/A for Fiscal Year Ended December 31, 2023 — 10-K/A · Apr 29, 2024 Risk: low
  CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) filed a Amended Annual Report (10-K/A) with the SEC on April 29, 2024. Creative Medical Technology Holdings, I
• Creative Medical Technology Holdings, Inc. Files 2023 Annual Report — 10-K · Mar 22, 2024 Risk: low
  CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) filed a Annual Report (10-K) with the SEC on March 22, 2024. The company filed its 10-K for the fiscal year en

Risk Profile

Risk Assessment: Of CELZ's 28 recent filings, 4 were flagged as high-risk, 13 as medium-risk, and 11 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Creative Medical Technology Holdings, INC.'s most recent 10-Q filing (Nov 7, 2025):

• Revenue: $3,000
• Net Income: -$1,235,934
• EPS: N/A
• Debt-to-Equity: N/A
• Cash Position: $5,375,511
• Operating Margin: N/A
• Total Assets: N/A
• Total Debt: N/A

Key Executives

• Timothy Warbington
• Donald Dickerson
• Michael H. Finger
• Susan Snow
• Bruce S. Urdang
• Chief Executive Officer

Industry Context

Creative Medical Technology Holdings, Inc. operates in the biotechnology and medical technology sector, a field characterized by rapid innovation, significant research and development costs, and stringent regulatory oversight. Companies in this space often rely on equity financing and strategic partnerships to fund operations and bring products to market. The competitive landscape includes both established players and emerging startups, with success often hinging on intellectual property, clinical trial outcomes, and market adoption.

Top Tags

financials (7) · corporate-governance (3) · Biotechnology (3) · 10-Q (3) · filing (3) · amendment (3) · 10-K (3) · proxy-statement (3) · regulatory-filing (2) · Corporate Governance (2)

Key Numbers

• Shares underlying Inducement Warrants: 2,790,340 — Amount of shares requiring stockholder approval for exercise
• Exercise price per share of Inducement Warrants: $2.86 — Current exercise price, reduced from $3.75
• Date Inducement Warrants were issued: October 29, 2025 — Also the record date for the Special Meeting
• Date of Special Meeting of Stockholders: December 26, 2025 — Meeting to vote on warrant exercise approval
• Shares of Common Stock outstanding: 2,850,532 — As of the record date, October 29, 2025
• Frequency of additional meetings: 90 days — Required if stockholder approval is not obtained
• Fee for proxy solicitation firm: $8,000 — Paid to Okapi Partners LLC for services
• Shares underlying Existing Warrants: 1,116,136 — Exercised on October 29, 2025, in exchange for Inducement Warrants
• Original exercise price of Existing Warrants: $3.75 — Also the initial exercise price of Inducement Warrants before reduction
• Exercisability period of Inducement Warrants: 5 years — Following stockholder approval
• Net Loss (Q3 2025): $1,235,934 — Increased from $1,040,135 in Q3 2024
• Net Loss (YTD Q3 2025): $4,107,334 — Widened from $3,639,407 in YTD Q3 2024
• Revenue (YTD Q3 2025): $3,000 — Minimal, down from $8,000 in YTD Q3 2024
• Cash Balance (Sept 30, 2025): $5,375,511 — Decreased from $5,940,402 at Dec 31, 2024
• Proceeds from Warrant Exercise: $3,364,000 — Significant financing activity for YTD Q3 2025

Related Companies

CMED

Frequently Asked Questions